reports
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: Additional CIDP data at AAN
argenx announced additional detail on its Phase 3 ADHERE data with Vyvgart Hytrulo, showcasing its speed of onset and depth of response. We believe that Vyvgart Hytrulo is well positioned vs. the approved standard-of-care IVIg/SCIg across patient types, and look forward to the FDA decision (PDUFA: June 21, 2024). € 435 TP and Buy rating reiterated.
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive ...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
- David Seynnaeve
- PhD
argenx - New CIDP & gMG data further underlines VYVGART (Hytrulo)'s va...
• ARGX shared additional results from the ADHERE (open-label) study and real-world data from gMG patients at the AAN Annual Meeting. • Data indicates rapid, deep, and clinically meaningful/sustained improvements in CIDP & with ability to reduce steroid burden (gMG). • We expect a positive outcome of the decision on regulatory approval for CDP by June 21 (85% LoA, +4% impact on TP) and currently project low double-digit million in sales this year. This might seem rather conservative (vs. gMG init...
- Gerardo Ibanez
- Steven Boumans
ODDO : From landbanks to goldmines: development pipelines in the logis...
The logistics market is our preferred real estate segment, where the coming growth remains undervalued. We prefer the high growth stock within this segment, CTP. We also have Outperform recommendations on Argan, Montea and VGP. We believe WDP is fully valued, though. - >A favourable environment for industrial and logistics real estate - We think the industrial and logistics (“I&L”) segment is the first major real estate market that has bottomed out. We see strong deman...
Nextensa : Convocation to the ordinary and extraordinary general share...
Nextensa : Convocation to the ordinary and extraordinary general shareholders’ meetings of 21 May 2024 PRESS RELEASE REGULATED INFORMATIONBrussels, 11 April 2024 – 5.40 PM Convocation to the ordinary and extraordinary general shareholders’ meetings of 21 May 2024 The board of directors of Nextensa invites the shareholders to attend the ordinary and extraordinary general shareholders’ meetings that will be held on Tuesday 21 May 2024 in Maison de la Poste, Picardstraat 5 box 7, 1000 Brussels. The ordinary general meeting will commence at 17.00h, immediately followed by the extraordin...
Nextensa : Oproeping tot de gewone en buitengewone algemene vergaderin...
Nextensa : Oproeping tot de gewone en buitengewone algemene vergaderingen van aandeelhouders van 21 mei 2024 PERSBERICHT GEREGLEMENTEERDE INFORMATIEBrussel, 11 april 2024 17u40 Oproeping tot de gewone en buitengewone algemene vergaderingen van aandeelhouders van 21 mei 2024 De raad van bestuur van Nextensa nodigt de aandeelhouders uit om deel te nemen aan de gewone en buitengewone algemene vergaderingen die zullen gehouden worden op dinsdag 21 mei 2024 in Maison de la Poste, Picardstraat 5 bus 7, 1000 Brussel. De gewone algemene vergadering vangt aan om 17u00, onmiddellijk gevolgd d...
Nextensa : Convocation à l’assemblée générale ordinaire et extraordina...
Nextensa : Convocation à l’assemblée générale ordinaire et extraordinaire des actionnaires du 21 mai 2024 COMMUNIQUÉ DE PRESSE INFORMATION RÉGLEMENTÉE Bruxelles, le 11 avril 2024 17h40 Convocation à l’assemblée générale ordinaire et extraordinaire des actionnaires du 21 mai 2024 Le conseil d’administration de Nextensa invite les actionnaires à participer à l’assemblée générale ordinaire et extraordinaire qui se tiendront le mardi 21 mai 2024 à la Maison de la Poste à Rue Picard 5 boîte 7, 1000 Bruxelles. L'assemblée générale ordinaire commencera à 17h00 et sera immédiatement suivi...
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Guy Sips
Agfa Undergoing a life changing transformation journey
Model update after FY23 as Agfa is undergoing a life-changing transformation to become a future-proof, profitable company with a mission. Agfa aims a) to improve patients' lives by contributing to the quality of diagnosis; b) participate in the development of green hydrogen to help decarbonise the world; c) develop innovative digital printing solutions that reduce the environmental footprint.
- Frank Claassen
Tessenderlo - From tailwind to headwind
• Following the weak H2-23 results and prudent outlook of stable EBITDA for 2024, we have lowered our FY24/FY25 EBITDA estimates by 17-19%. • Most divisions are facing headwinds and H1-24 is expected to be down yoy. • We lower our TP from EUR 33 to EUR 28, based on our 2025E SOTP (was 2024E). Hold maintained.
- Wim Hoste
Tessenderlo Model update post FY23 results
We have lowered our FY24 and FY25 adjusted EBITDA forecasts by respectively 25% and 21% following weaker than expected FY23 results and FY24 guidance. Tessenderlo is a very diversified group with limited synergies between the various operations. Valuation is clearly attractive and we expect the strong balance sheet will prompt the board to decide on an extension of the current share buyback program, allowing the company to benefit from the low share price to catch up additional stock. We maintai...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Wim Hoste
Tessenderlo Conference call feedback
Below are the highlights from the conference call. Tessenderlo posted much weaker than expected FY23 results with adjusted EBITDA down about 32% y/y (on a proforma basis) and c 15% below our and 16% below consensus. Key shortfalls were in BioValorization and the Machines & Technologies divisions. The FY24 calls for flat adjusted EBITDA which is about 27% below our and consensus forecasts. Tessenderlo is a very diversified group with limited synergies between the various operations. We consider v...
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
Argenx : Positive phase II results in Sjögren’s disease
>Phase II results support a move to phase III - Argenx announced positive results for the phase II RHO study evaluating efgartigimod in patients suffering from Sjögren’s disease (SjD). The company has not announced any figures for the results at this stage since they will be presented at an upcoming medical conference. Based on these results, the company envisages continuing the development of efgartigimod in phase III, which could lead to a commercial launch in this ...
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
Argenx : Résultats de phase 2 positifs dans le syndrome de Sjögren
>Phase 2 soutenant un passage en phase 3 - Argenx annonce des résultats positifs de la phase 2 RHO évaluant efgartigimod chez des patients atteints du syndrome de Sjögren (SjD). La société ne communique aucun résultat chiffré à ce stade puisqu’ils seront présentés lors d’un prochain congrès médical. Sur la base de ces résultats, la société envisage de poursuivre le développement d’efgartigimod en phase 3, ce qui pourrait conduire à un lancement commercial dans cette i...
- ING Helpdesk
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.